University of California, San Francisco Logo

University of California, San Francisco | About UCSF | Search UCSF | UCSF Medical Center

Home > CME > HCV Infection > Slides
Management and Treatment of HCV infection: Entering a New Era in 2011
Slide 1.
Management and Treatment of HCV infection: Entering a New Era in 2011
Slide 1.
Objectives
Slide 2.
Goals of Therapy
Slide 3.
SVR Reduces Rate of Liver-Related Events in HIV/HCV-Coinfected Adults
Slide 4.
Characteristics of Persons for Whom Therapy is Currently Contraindicated
Slide 5.
Characteristics of Persons for Whom Therapy Should be Individualized
Slide 6.
HIV HCV Studies
Slide 7.
HIV HCV Studies
Slide 8.
Table 1: Factors Associated with Sustained Virologic Response to HCV Therapy in HIV Patients
Slide 9.
Virologic Response Timepoints
Slide 10.
RVR & Complete EVR are Strong Predictors of SVR
Slide 11.
HIV HCV Treatment Summary 2011
Slide 12.
What's Coming in 2011?
Slide 13.
Important Targets for DAA Therapy in the HCV Genome
Slide 14.
Phase 3 Clinical Trials of HCV PIs in Genotype 1 Patients
Slide 15.
Case #1
Slide 16.
SVR Rates with BOC and TVR in GT1 Treatment-Naïve HCV-Monoinfected Patients
Slide 17.
TVR vs. BOC Administration in Phase III Studies of GT1 Naïve HCV-Monoinfected Pts
Slide 18.
Telaprevir & Bocepravir - Safety
Slide 19.
Preliminary ITT Results in Genotype 1 HIV/HCV pts at Week 4 of Telapravir12PR
Slide 20.
Preliminary ITT Results at Week 12 of T12PR in Genotype 1 HIV/HCV-Coinfected Patients
Slide 21.
Preliminary ITT Results at Week 12 of T12PR in Genotype 1 HIV/HCV-Coinfected Patients
Slide 22.
Change in PK Parameter in Healthy Volunteers
Slide 	23.
Little Change in Mean (SD) HIV RNA from Baseline in Those on ART
Slide 24.
Most Common Reported Adverse Events in HIV/HCV-Coinfected Patients
Slide 25.
Predefined Stopping Rules
Slide 26.
Case #2
Slide 27.
TRV vs BOC in TX Experienced GT 1 HCV-Monoinfected Patients
Slide 28.
SVR Rates higher with BOC & TPV in GT1 Tx-Experienced HCV-monoinfected patients
Slide 29.
Suboptimal Virologic Responses
Slide 30.
Type of Suboptimal Virologic Response in Past Impacts on SVR with Retreatment with TVR/PR
Slide 31.
Should Lead-In Response Determine Continuation to Triple Rx?
Slide 32.
Effect of Race/Ethnicity
Slide 33.
SVR by Race/Ethnicity in Genotype 1 HCV-Monoinfected Treatment Naïve Patients
Slide 34.
Effect of Fibrosis Stage
Slide 35.
SVR by Fibrosis Stage in Genotype 1 HCV-Monoinfected Treatment Naïve Patients
Slide 36.
Effect of IL28B Genotype
Slide 37.
IL28B Genetic Variation and Viral Clearance with PEG/RBV
Slide 38.
Little Improvement in SVR with BOC in Naïve Patients with CC Allele; SVR Improved in Those with T Allele
Slide 39.
Clinical Applications of IL28b Testing in HCV Genotype 1 Infection
Slide 40.
HCV PI Resistance
Slide 41.
Clinical Impact of Resistance Associated Variants (RAV)
Slide 42.
HCV Treatment in HIV: Future
Slide 43.
INFORM-1: RCT of RG7128 (Nucleoside NS5A Polymerase Inhibitor) Plus NS3/4a Protease Inhibitor Danoprevir in GT1 Patients
Slide 44.
Internet Resources
Slide 45.

We request that all users complete the brief posttest and evaluation to provide feedback to course planners and presenters. Those requesting CME credit are required to complete all components to receive credit. Begin with the posttest.